Laura Cunha Rodrigues

Laura Cunha Rodrigues

Auto-generated profile, based on publicly available information

Laura Cunha Rodrigues

London School of Hygiene & Tropical Medicine, London, United Kingdom

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPunam Mangtani
Punam Mangtani
IAIbrahim Abubakar
Ibrahim Abubakar
CACono Ariti
Cono Ariti
RBRebecca Beynon
Rebecca Beynon
LPLaura Pimpin
Laura Pimpin
JSJonathan A. Sterne
Jonathan A. Sterne
Background. Randomized trials assessing BCG vaccine protection against tuberculosis have widely varying results, for reasons that are not well understood. Methods. We examined associations of trial setting and design with BCG efficacy against pulmonary and miliary or meningeal tuberculosis by conducting a systematic review, meta-analyses, and meta-regression. Results. We identified 18 trials reporting pulmonary tuberculosis and 6 reporting miliary or meningeal tuberculosis. Univariable meta-regression indicated efficacy against pulmonary tuberculosis varied according to 3 characteristics. Protection appeared greatest in children stringently tuberculin tested, to try to exclude prior infection with Mycobacterium tuberculosis or sensitization to environmental mycobacteria (rate ratio [RR], 0.26; 95% confidence interval [CI], .18–.37), or infants (RR, 0.41; 95% CI, .29–.58). Protection was weaker in children not stringently tested (RR, 0.59; 95% CI, .35–1.01) and older individuals stringently or not stringently tested (RR, 0.88; 95% CI, .59–1.31 and RR, 0.81; 95% CI, .55–1.22, respectively). Protection was higher in trials further from the equator where environmental mycobacteria are less and with lower risk of diagnostic detection bias. These associations were attenuated in a multivariable model, but each had an independent effect. There was no evidence that efficacy was associated with BCG strain. Protection against meningeal and miliary tuberculosis was also high in infants (RR, 0.1; 95% CI, .01–.77) and children stringently tuberculin tested (RR, 0.08; 95% CI, .03–.25). Conclusions. Absence of prior M. tuberculosis infection or sensitization with environmental mycobacteria is associated with higher efficacy of BCG against pulmonary tuberculosis and possibly against miliary and meningeal tuberculosis. Evaluations of new tuberculosis vaccines should account for the possibility that prior infection may mask or block their effects.

17 April 1999 in BMJ
Verified
Journal Article
Closed access
PDF file
JWJeremy G Wheeler
Jeremy G Wheeler
DSDinesh Sethi
Dinesh Sethi
JCJohn M Cowden
John M Cowden
PWPatrick G Wall
Patrick G Wall
LRLaura C Rodrigues
Laura C Rodrigues
PRPaul J Roderick
Paul J Roderick
Objective: To establish the incidence and aetiology of infectious intestinal disease in the community and presenting to general practitioners. Comparison with incidence and aetiology of cases reaching national laboratory based surveillance. Design: Population based community cohort incidence study, general practice based incidence studies, and case linkage to national laboratory surveillance. Setting: 70 general practices throughout England. Participants: 459 975 patients served by the practices. Community surveillance of 9776 randomly selected patients. Main outcome measures: Incidence of infectious intestinal disease in community and reported to general practice. Results: 781 cases were identified in the community cohort, giving an incidence of 19.4/100 person years (95% confidence interval 18.1 to 20.8). 8770 cases presented to general practice (3.3/100 person years (2.94 to 3.75)). One case was reported to national surveillance for every 1.4 laboratory identifications, 6.2 stools sent for laboratory investigation, 23 cases presenting to general practice, and 136 community cases. The ratio of cases in the community to cases reaching national surveillance was lower for bacterial pathogens (salmonella 3.2:1, campylobacter 7.6:1) than for viruses (rotavirus 35:1, small round structured viruses 1562:1). There were many cases for which no organism was identified. Conclusions: Infectious intestinal disease occurs in 1 in 5 people each year, of whom 1 in 6 presents to a general practitioner. The proportion of cases not recorded by national laboratory surveillance is large and varies widely by microorganism.Ways of supplementing the national laboratory surveillance system for infectious intestinal diseases should be considered.

1 November 2000 in The Lancet
Verified
Journal Article
Closed access
ABAnita Hj van Den Biggelaar
Anita Hj van Den Biggelaar
RRRonald van Ree
Ronald van Ree
LRLaura C Rodrigues
Laura C Rodrigues
BLBertrand Lell
Bertrand Lell
ADAndré M Deelder
André M Deelder
MYMaria Yazdanbakhsh
Maria Yazdanbakhsh

4 August 2014 in BMJ
Verified
Journal Article
Open access
PDF file
ARA. Roy
A. Roy
MEM. Eisenhut
M. Eisenhut
RHR. J. Harris
R. J. Harris
LRL. C. Rodrigues
L. C. Rodrigues
SSS. Sridhar
S. Sridhar
IAIbrahim Abubakar
Ibrahim Abubakar
Objectives To determine whether BCG vaccination protects against Mycobacterium tuberculosis infection as assessed by interferon γ release assays (IGRA) in children. Design Systematic review and meta-analysis. Searches of electronic databases 1950 to November 2013, checking of reference lists, hand searching of journals, and contact with experts. Setting Community congregate settings and households. Inclusion criteria Vaccinated and unvaccinated children aged under 16 with known recent exposure to patients with pulmonary tuberculosis. Children were screened for infection with M tuberculosis with interferon γ release assays. Data extraction Study results relating to diagnostic accuracy were extracted and risk estimates were combined with random effects meta-analysis. Results The primary analysis included 14 studies and 3855 participants. The estimated overall risk ratio was 0.81 (95% confidence interval 0.71 to 0.92), indicating a protective efficacy of 19% against infection among vaccinated children after exposure compared with unvaccinated children. The observed protection was similar when estimated with the two types of interferon γ release assays (ELISpot or QuantiFERON). Restriction of the analysis to the six studies (n=1745) with information on progression to active tuberculosis at the time of screening showed protection against infection of 27% (risk ratio 0.73, 0.61 to 0.87) compared with 71% (0.29, 0.15 to 0.58) against active tuberculosis. Among those infected, protection against progression to disease was 58% (0.42, 0.23 to 0.77). Conclusions BCG protects against M tuberculosis infection as well as progression from infection to disease. Trial registration PROSPERO registration No CRD42011001698 (www.crd.york.ac.uk/prospero/).

1 December 1993 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
LRLaura C Rodrigues
Laura C Rodrigues
VDVinod K Diwan
Vinod K Diwan
JWJeremy G Wheeler
Jeremy G Wheeler
The protective effect of BCG against tuberculosis (TB) estimated in randomized controlled trials and observational studies ranges from negative to dose to a 100%. One of the many explanations offered for this is that different immunological mechanisms may be associated with protective effect against different forms and sites of disease. In this investigation, we recalculated vaccine protective effect separately for pulmonary disease and for meningeal/miliary disease in randomized controlled trials and case-control studies, tested for heterogeneity in site-specific estimates of protective effect and calculated a summary measure when appropriate. We found protective effect against pulmonary disease to be heterogenous to a statistically significant degree, and thus we did not calculate a summary measure of protection. Protective effect against meningeal and miliary TB was higher than against pulmonary disease and, except for a single study with two cases only, appeared to be homogeneous. Summary BCG protective effect against miliary or meningeal TB in randomized controlled trials was 86% (95% confidence interval [Cl] 65, 95) and in case-control studies 75% (95% Cl: 61, 84). The fact that protective effect appeared to be homogeneous against meningitis and miliary TB but not against pulmonary disease may result from the fact that patients with meningitis are on average younger and thus less likely to have been exposed to atypical bacteria; to a waning of the protective effect of BCG; or from the diversity of mechanisms of pathogenesis of pulmonary disease, which can originate from reinfection, reactivation or primary progression.

27 June 2011 in Gut
Verified
Journal Article
Open access
PDF file
CTClarence C Tam
Clarence C Tam
LRLaura C Rodrigues
Laura C Rodrigues
LVLaura Viviani
Laura Viviani
JDJulie P Dodds
Julie P Dodds
MEMeirion R Evans
Meirion R Evans
SOSarah J O'BRien
Sarah J O'BRien
Objectives: To estimate, overall and by organism, the incidence of infectious intestinal disease (IID) in the community, presenting to general practice (GP) and reported to national surveillance. Design: Prospective, community cohort study and prospective study of GP presentation conducted between April 2008 and August 2009. Setting: Eighty-eight GPs across the UK recruited from the Medical Research Council General Practice Research Framework and the Primary Care Research Networks. Participants: 6836 participants registered with the 88 participating practices in the community study; 991 patients with UK-acquired IID presenting to one of 37 practices taking part in the GP presentation study. Main outcome measures: IID rates in the community, presenting to GP and reported to national surveillance, overall and by organism; annual IID cases and GP consultations by organism. Results: The overall rate of IID in the community was 274 cases per 1000 person-years (95% CI 254 to 296); the rate of GP consultations was 17.7 per 1000 person-years (95% CI 14.4 to 21.8). There were 147 community cases and 10 GP consultations for every case reported to national surveillance. Norovirus was the most common organism, with incidence rates of 47 community cases per 1000 person-years and 2.1 GP consultations per 1000 person-years. Campylobacter was the most common bacterial pathogen, with a rate of 9.3 cases per 1000 person-years in the community, and 1.3 GP consultations per 1000 person-years. We estimate that there are up to 17 million sporadic, community cases of IID and 1 million GP consultations annually in the UK. Of these, norovirus accounts for 3 million cases and 130 000 GP consultations, and Campylobacter is responsible for 500 000 cases and 80 000 GP consultations. Conclusions: IID poses a substantial community and healthcare burden in the UK. Control efforts must focus particularly on reducing the burden due to Campylobacter and enteric viruses.